Literature DB >> 9277011

Required duration of combined annual ivermectin treatment and vector control in the Onchocerciasis Control Programme in west Africa.

A P Plaisier1, E S Alley, G J van Oortmarssen, B A Boatin, J D Habbema.   

Abstract

In the extension areas of the Onchocerciasis Control Programme in West Africa, aerial larviciding is supplemented with annual ivermectin treatment, mainly to achieve better control of morbidity. The purpose of this study is to determine whether and to what extent the addition of annual ivermectin treatment permits earlier cessation of vector control than originally recommended. The effectiveness of combined ivermectin distribution and vector control was assessed using an epidemiological model. Model predictions suggest that, dependent on the pre-control endemicity of the area and the proportion of persons treated during each ivermectin round, large-scale annual treatment permits a considerable reduction in the duration of vector control. Taking into account uncertainty about the efficacy of ivermectin, our results indicate that, provided treatment coverage is at least 65% and there is no importation of infection from elsewhere, 12 years of combined control will be sufficient to reduce the risk of recrudescence to below 1% in even the most afflicted areas.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9277011      PMCID: PMC2486951     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  15 in total

1.  The predicted and observed decline in onchocerciasis infection during 14 years of successful control of Simulium spp. in west Africa.

Authors:  J Remme; G De Sole; G J van Oortmarssen
Journal:  Bull World Health Organ       Date:  1990       Impact factor: 9.408

2.  Impact of combined large-scale ivermectin distribution and vector control on transmission of Onchocerca volvulus in the Niger basin, Guinea.

Authors:  P Guillet; A Sékétéli; E S Alley; H Agoua; B A Boatin; Y Bissan; L K Akpoboua; D Quillévéré; E M Samba
Journal:  Bull World Health Organ       Date:  1995       Impact factor: 9.408

3.  Adverse reactions after large-scale treatment of onchocerciasis with ivermectin: combined results from eight community trials.

Authors:  G De Sole; J Remme; K Awadzi; S Accorsi; E S Alley; O Ba; K Y Dadzie; J Giese; M Karam; F M Keita
Journal:  Bull World Health Organ       Date:  1989       Impact factor: 9.408

4.  Studies on the reinvasion of the Onchocerciasis Control Programme in the Volta River Basin by Simulium damnosum s.I. with emphasis on the south-western areas.

Authors:  R Garms; J F Walsh; J B Davies
Journal:  Tropenmed Parasitol       Date:  1979-09

5.  Changes in ocular onchocerciasis after two rounds of community-based ivermectin treatment in a holo-endemic onchocerciasis focus.

Authors:  K Y Dadzie; J Remme; G De Sole
Journal:  Trans R Soc Trop Med Hyg       Date:  1991 Mar-Apr       Impact factor: 2.184

6.  The impact of five years of annual ivermectin treatment on skin microfilarial loads in the onchocerciasis focus of Asubende, Ghana.

Authors:  E S Alley; A P Plaisier; B A Boatin; K Y Dadzie; J Remme; G Zerbo; E M Samba
Journal:  Trans R Soc Trop Med Hyg       Date:  1994 Sep-Oct       Impact factor: 2.184

7.  Ocular findings in a double-blind study of ivermectin versus diethylcarbamazine versus placebo in the treatment of onchocerciasis.

Authors:  K Y Dadzie; A C Bird; K Awadzi; H Schulz-Key; H M Gilles; M A Aziz
Journal:  Br J Ophthalmol       Date:  1987-02       Impact factor: 4.638

8.  The risk and dynamics of onchocerciasis recrudescence after cessation of vector control.

Authors:  A P Plaisier; G J van Oortmarssen; J Remme; E S Alley; J D Habbema
Journal:  Bull World Health Organ       Date:  1991       Impact factor: 9.408

9.  The effects of repetitive community-wide ivermectin treatment on transmission of Onchocerca volvulus in Guatemala.

Authors:  E W Cupp; J O Ochoa; R C Collins; M S Cupp; C Gonzales-Peralta; J Castro; G Zea-Flores
Journal:  Am J Trop Med Hyg       Date:  1992-08       Impact factor: 2.345

10.  Irreversible effects of ivermectin on adult parasites in onchocerciasis patients in the Onchocerciasis Control Programme in West Africa.

Authors:  A P Plaisier; E S Alley; B A Boatin; G J Van Oortmarssen; H Remme; S J De Vlas; L Bonneux; J D Habbema
Journal:  J Infect Dis       Date:  1995-07       Impact factor: 5.226

View more
  19 in total

1.  Compliance with eight years of annual ivermectin treatment of onchocerciasis in Cameroon and Nigeria.

Authors:  William R Brieger; Joseph C Okeibunor; Adenike O Abiose; Samuel Wanji; Elizabeth Elhassan; Richard Ndyomugyenyi; Uche V Amazigo
Journal:  Parasit Vectors       Date:  2011-07-27       Impact factor: 3.876

2.  Onchocerca volvulus-specific antibody and cytokine responses in onchocerciasis patients after 16 years of repeated ivermectin therapy.

Authors:  C S Mai; D M Hamm; M Banla; A Agossou; H Schulz-Key; C Heuschkel; P T Soboslay
Journal:  Clin Exp Immunol       Date:  2007-03       Impact factor: 4.330

3.  Feasibility of Onchocerciasis Elimination Using a "Test-and-not-treat" Strategy in Loa loa Co-endemic Areas.

Authors:  David J Blok; Joseph Kamgno; Sebastien D Pion; Hugues C Nana-Djeunga; Yannick Niamsi-Emalio; Cedric B Chesnais; Charles D Mackenzie; Amy D Klion; Daniel A Fletcher; Thomas B Nutman; Sake J de Vlas; Michel Boussinesq; Wilma A Stolk
Journal:  Clin Infect Dis       Date:  2021-06-15       Impact factor: 9.079

Review 4.  A research agenda for helminth diseases of humans: intervention for control and elimination.

Authors:  Roger K Prichard; María-Gloria Basáñez; Boakye A Boatin; James S McCarthy; Héctor H García; Guo-Jing Yang; Banchob Sripa; Sara Lustigman
Journal:  PLoS Negl Trop Dis       Date:  2012-04-24

Review 5.  A research agenda for helminth diseases of humans: towards control and elimination.

Authors:  Boakye A Boatin; María-Gloria Basáñez; Roger K Prichard; Kwablah Awadzi; Rashida M Barakat; Héctor H García; Andrea Gazzinelli; Warwick N Grant; James S McCarthy; Eliézer K N'Goran; Mike Y Osei-Atweneboana; Banchob Sripa; Guo-Jing Yang; Sara Lustigman
Journal:  PLoS Negl Trop Dis       Date:  2012-04-24

6.  Onchocerciasis transmission in Ghana: persistence under different control strategies and the role of the simuliid vectors.

Authors:  Poppy H L Lamberton; Robert A Cheke; Peter Winskill; Iñaki Tirados; Martin Walker; Mike Y Osei-Atweneboana; Nana-Kwadwo Biritwum; Anthony Tetteh-Kumah; Daniel A Boakye; Michael D Wilson; Rory J Post; María-Gloria Basañez
Journal:  PLoS Negl Trop Dis       Date:  2015-04-21

7.  Onchocerciasis transmission in Ghana: biting and parous rates of host-seeking sibling species of the Simulium damnosum complex.

Authors:  Poppy H L Lamberton; Robert A Cheke; Martin Walker; Peter Winskill; Mike Y Osei-Atweneboana; Iñaki Tirados; Anthony Tetteh-Kumah; Daniel A Boakye; Michael D Wilson; Rory J Post; María-Gloria Basáñez
Journal:  Parasit Vectors       Date:  2014-11-21       Impact factor: 3.876

8.  Elimination of African onchocerciasis: modeling the impact of increasing the frequency of ivermectin mass treatment.

Authors:  Luc E Coffeng; Wilma A Stolk; Achim Hoerauf; Dik Habbema; Roel Bakker; Adrian D Hopkins; Sake J de Vlas
Journal:  PLoS One       Date:  2014-12-29       Impact factor: 3.240

9.  African Programme For Onchocerciasis Control 1995-2015: model-estimated health impact and cost.

Authors:  Luc E Coffeng; Wilma A Stolk; Honorat G M Zouré; J Lennert Veerman; Koffi B Agblewonu; Michele E Murdoch; Mounkaila Noma; Grace Fobi; Jan Hendrik Richardus; Donald A P Bundy; Dik Habbema; Sake J de Vlas; Uche V Amazigo
Journal:  PLoS Negl Trop Dis       Date:  2013-01-31

10.  Onchocerciasis: the pre-control association between prevalence of palpable nodules and skin microfilariae.

Authors:  Luc E Coffeng; Sébastien D S Pion; Simon O'Hanlon; Simon Cousens; Adenike O Abiose; Peter U Fischer; Jan H F Remme; K Yankum Dadzie; Michele E Murdoch; Sake J de Vlas; María-Gloria Basáñez; Wilma A Stolk; Michel Boussinesq
Journal:  PLoS Negl Trop Dis       Date:  2013-04-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.